From the perspective of market distribution, there are more than 40 peptide drugs on the market in my country, which are mainly distributed in seven fields, including immunity, digestive tract, anti-tumor, orthopedics, obstetrics, diabetes and cardiovascular. Among them, immune drugs dominate, accounting for more than 50% of the domestic market

From the perspective of market distribution, there are more than 40 peptide drugs on the market in my country, which are mainly distributed in seven fields, including immunity, digestive tract, anti-tumor, orthopedics, obstetrics, diabetes and cardiovascular. Among them, immune drugs dominate, accounting for more than 50% of the domestic market;

digestive tract and anti-tumor fields are second, each accounting for about 20%; orthopedics, obstetrics, diabetes, and cardiovascular markets are smaller, accounting for 7% of the total market. The market is dominated by primary products and has not yet entered a mature period.

From the perspective of the global peptide market, 85% of the market is concentrated in the treatment of chronic diseases such as tumors and diabetes. First aid and surgical aids account for only about 15%. The treatment of chronic diseases is the real bonanza of the peptide industry.

In contrast, in the peptide market in my country, immunity, digestive tract, obstetrics, cardiovascular (angina pectoris, myocardial infarction, etc.) are all short-term medications or emergency medications. Oncology, orthopedics (osteoporosis treatment), diabetes and other chronic disease treatments only account for With a market share of 26%, there is still a lot of room for development.

At present, the domestic peptide drug market is dominated by imported drugs, and expensive prices have become an important factor in restraining the volume of peptide drugs. 2014-2022 is the peak period for patent expiration of blockbuster varieties of peptide drugs. Many varieties have not yet been listed in China or only imported original research drugs have been listed. Among them, there are many glatiramer and liraru with global sales of more than 1 billion U.S. dollars. Peptides, exenatide, goserelin, etc.

The treatment fields corresponding to the company’s main products are as follows:

The company’s peptide drugs in the field of cardiovascular and cerebrovascular diseases are mainly bivalrudine and eptifibatide, and the two products are mainly used for anticoagulant therapy. Anticoagulant drugs can be divided into factor Xa inhibitors (rivaroxaban, apixaban, fondaparinux, etc.), direct thrombin inhibitors (polypeptide drugs bivalridine, dabigatran etexilate, Argatroban, etc.), antiplatelet drugs (clopidogrel, ticagrelor, tirofiban, peptide drug eptifibatide, etc.).

Cardiovascular and cerebrovascular diseases such as cerebral thrombosis, cerebral infarction, myocardial infarction, coronary heart disease, atherosclerosis, etc. kill 12 million people every year worldwide, close to a quarter of the world’s total deaths, and are the number one enemy of human health. .

According to a research report by Ping An Securities, the global anticoagulant drug original research market in 2017 was approximately US$14.9 billion. In 2017, the size of the anticoagulant drug market in my country’s sample hospitals was about 9 billion yuan.

In 2019, the global and domestic sample agency sales of customized Bivare were US$116.67 million and 534.34 million, respectively. The global sales have declined but the domestic market has been in the past three years. The growth rate remained above 40%. Etibatide preparations In 2019, the sales of eptifibatide in domestic sample institutions reached 71.39 million, with an average annual compound growth rate of 326.55% in the past three years.

According to the IQVIA database, Fresenius (Fresenius) company’s custom-made bivalve in 2019 ranked first with a market share of 30.82% in the United States, and the company is the number one supplier of its raw materials.

With the adjustment of my country’s fertility policy, more than 15 million newborns have been born in my country each year in recent years. At the same time, the number of elderly pregnant women is increasing, leading to an increase in the probability of fetal and maternal complications and complications.

Refractory postpartum hemorrhage and premature delivery are the focus and difficulty of obstetric clinical work, and are one of the main causes of maternal death and perinatal death in China. Postpartum hemorrhage drugs mainly include polypeptide drugs oxytocin, carbetocin; small molecule chemical drugs carprost, tromethamine, misoprostol, ergonovine and so on. Premature delivery drugs include ritodrine, nifedipine, atosiban and so on.

Oxytocin is the most commonly used drug to prevent postpartum hemorrhage, and it is recommended as a first-line preventive drug by clinical guidelines of countries around the world. Carbetocin is a long-acting oxytocin, which is similar to the oxytocin released from the posterior pituitary gland.